The current epidemic of sexually transmitted diseases (STDs) is characterized by a growing list of organisms (bacterial, viral, fungal and protozoan) responsible for a large number of serious diseases, disproportionately affecting adolescent and minority populations. The problem is exacerbated by the emergence of antibiotic and drug resistant organisms, and is currently one of the major public health crises in the United States. The existing approaches to the control of this epidemic are prevention, detection and treatment. Currently, prevention means education, easy access to barrier methods (primarily condoms), and to a lesser extent, the use of microbicides. Unfortunately, the only widely used microbicide is nonoxynol-9 and both its efficacy and safety have recently been questioned. The purpose of this project is to develop new topical microbicides suitable for the prevention of a wide variety of sexually transmitted diseases (STDs) including AIDS. The research is focused on a patented technology involving amphoric surface active molecules, known as C31G. The C31G technology employs a mixture of two synthetic molecules, an alkyl amine oxide and an alkyl betaine, that form a mixed micelle demonstrating a broad spectrum antibacterial and antiviral activity. The present proposal is designed to carry out structure-function studies with a series of alkyl amine oxides and alkyl betaines in an attempt to selectively enhance microbicidal activity and decrease toxicity for mammalian cells. Once the ideal C31G formulae is obtained, additional studies will be carried out to formulate the microbicide into a form that has wide acceptability. This will involve the addition of excipients and the design of a new delivery system which will allow for safe and discrete application of vaginal microbicides in a form that is under female control, and can be used without male knowledge. This proposal is part of a larger program project whereby new- microbicides will be evaluated against a large panel of STD organisms including bacteria (Treponema, Chlamydia, Neisseria), yeast (Candida), and viruses (HIV, HSV, HPV). To demonstrate low mammalian cell toxicity both in vitro (cell culture) and animal models will be employed.

Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
1996
Total Cost
Indirect Cost
Passic, Shendra R; Ferguson, Mary Lee; Catalone, Bradley J et al. (2010) Structure-activity relationships of polybiguanides with activity against human immunodeficiency virus type 1. Biomed Pharmacother 64:723-32
Pavlovic, Jelena; Floros, Joanna; Phelps, David S et al. (2008) Differentiation of xenografted human fetal lung parenchyma. Early Hum Dev 84:181-93
Beer, Brigitte E; Doncel, Gustavo F; Krebs, Fred C et al. (2006) In vitro preclinical testing of nonoxynol-9 as potential anti-human immunodeficiency virus microbicide: a retrospective analysis of results from five laboratories. Antimicrob Agents Chemother 50:713-23
Fang, L; Meyers, C; Budgeon, L R et al. (2006) Induction of productive human papillomavirus type 11 life cycle in epithelial cells grown in organotypic raft cultures. Virology 347:28-35
Hartmann, Sandra Urdaneta; Wigdahl, Brian; Neely, Elizabeth B et al. (2006) Biochemical analysis of human milk treated with sodium dodecyl sulfate, an alkyl sulfate microbicide that inactivates human immunodeficiency virus type 1. J Hum Lact 22:61-74
Deka, Srilekha; Vanover, Jennifer; Dessus-Babus, Sophie et al. (2006) Chlamydia trachomatis enters a viable but non-cultivable (persistent) state within herpes simplex virus type 2 (HSV-2) co-infected host cells. Cell Microbiol 8:149-62
Hartmann, Sandra Urdaneta; Berlin, Cheston M; Howett, Mary K (2006) Alternative modified infant-feeding practices to prevent postnatal transmission of human immunodeficiency virus type 1 through breast milk: past, present, and future. J Hum Lact 22:75-88; quiz 89-93
Fang, L; Budgeon, L R; Doorbar, J et al. (2006) The human papillomavirus type 11 E1/E4 protein is not essential for viral genome amplification. Virology 351:271-9
Catalone, Bradley J; Kish-Catalone, Tina M; Neely, Elizabeth B et al. (2005) Comparative safety evaluation of the candidate vaginal microbicide C31G. Antimicrob Agents Chemother 49:1509-20
Catalone, Bradley J; Miller, Shendra R; Ferguson, Mary Lee et al. (2005) Toxicity, inflammation, and anti-human immunodeficiency virus type 1 activity following exposure to chemical moieties of C31G. Biomed Pharmacother 59:430-7

Showing the most recent 10 out of 35 publications